Back to results
US 2014/0178335 A1Published application
Use of il-12 to generate endogenous erythropoietin
AssigneeNeumedicines, Inc.
InventorLena A. Basile
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of exogenous interleukin-12 (IL-12) for increasing endogenous production of erythropoietin.
Claims26
A method for generating endogenous erythropoietin in a subject in need of increasing the levels of erythropoietin in the blood comprising administering a therapeutically effective dose of recombinant IL-12 to the subject, wherein the therapeutically effective dose of IL-12 elevates the endogenous erythropoietin blood concentration.
-5. (canceled)
-8. (canceled)
(canceled)
-24. (canceled)
(canceled)
Dependencies are inferred from the claim text.